Title : A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Pub. Date : 2014 Oct

PMID : 25102375






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). cabozantinib kinase insert domain receptor Homo sapiens
2 BACKGROUND: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). cabozantinib ret proto-oncogene Homo sapiens
3 BACKGROUND: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). cabozantinib ret proto-oncogene Homo sapiens